HK Stock Market Move | HBM HOLDINGS-B(02142) rose by more than 5%. The stock price has more than doubled in the past month. Recently, it has achieved overseas cooperation agreements worth about $1 billion.

HBM HOLDINGS-B(02142) rose by more than 5%, and its stock price has more than doubled in the past month. As of the time of writing, it has increased by 5.43% to HK$2.72, with a trading volume of HK$7.946 million. In terms of news, HBM Pharma recently announced a licensing agreement with Windward Bio AG for HBM9378/SKB378, a fully human monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) developed jointly by HBM Pharma and Corneb Pharma. According to the agreement, Windward Bio has been granted exclusive rights to research, develop, produce, and commercialize HBM9378/SKB378 globally (excluding Greater China and certain countries in Southeast and West Asia). HBM Pharma and Corneb Pharma are entitled to receive a total of up to $970 million in upfront and milestone payments, as well as single to double-digit percentage tiered royalty payments based on net sales. The upfront and recent milestone payments amount to a total of $45 million, including cash payments and equity in Windward Bio's parent company. Additionally, if Windward Bio undergoes a change in control or enters into further licensing agreements with third parties, HBM Pharma and Corneb Pharma will be entitled to additional payments. All payments under the licensing agreement will be equally shared between HBM Pharma and Corneb Pharma.